Loading...
OTCM
AFFY
Market cap59kUSD
Oct 08, Last price  
0.00USD
1D
6.25%
1Q
70.00%
Jan 2017
-97.34%
IPO
-100.00%
Name

Affymax Inc

Chart & performance

D1W1MN
OTCM:AFFY chart
P/E
—
P/S
0.05
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-66.78%
Revenues
1m
-98.55%
0103,000225,000151,00074,00011,726,00044,336,00082,851,000114,899,000112,521,00047,720,00094,370,0001,369,000
Net income
-14m
L-84.56%
-10,244,000-28,046,000-28,361,000-21,398,000-32,576,000-48,288,000-43,069,000-86,510,000-76,531,000-14,075,000-61,367,000-93,412,000-14,424,000
CFO
-67m
L+81.12%
2,279,000-19,949,000-24,765,00068,298,000-45,539,000-62,631,000-80,927,000-49,234,000-71,966,000-37,180,000-67,339,000
Dividend
Nov 28, 20140.05 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Affymax, Inc. presently lacks any substantial operational activities. In its earlier history, the firm concentrated on the creation of pharmaceutical agents designed to improve therapies for severe and frequently fatal health issues across the United States. Established in 2001, its corporate base is situated in New York, New York.

Key people

John Orwin
Independent Chairman of the Board · since 2013
Jonathan Couchman
President, Chief Executive Officer, Director · since 2014
Mark Thompson
Chief Financial Officer · since 2013
Grace Shin
General Counsel · since 2008
URL
http://www.affymax.com/
IPO date
Dec 15, 2006
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

No data to show